TPX-0005: A Multi-Faceted Approach to Overcoming Clinical Resistances from Current ALK or ROS1 Inhibitor Treatment in Lung Cancer

被引：0
|
作者：
Cut, J. Jean [1 ]
Zhai, Dayong [1 ]
Deng, Wei [1 ]
Huang, Zhongdong [1 ]
Rogers, Evan [1 ]
Ung, Jane [1 ]
Whitten, Jeffrey [1 ]
Li, Yishan [1 ]
机构：
[1] Tp Therapeut Inc, Oncol, San Diego, CA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期
关键词：
ALK; ros1; Src; Resistance;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.02a-009
引用
收藏
页码：S1164 / S1165
页数：2
相关论文
共 15 条
  • [1] Overcoming acquired drug resistance by TPX-0005, an ALK, ROS1 and pan-TRK inhibitor
    Deng, Wei
    Huang, John
    Zhai, Dayong
    Rogers, Evan
    Cui, Jean
    CANCER RESEARCH, 2017, 77
  • [2] ALK/ROS1/TRK Inhibitor TPX-0005 Effectively Overcomes Clinical Resistance Solvent Front Mutations
    Cui, J. J.
    Zhai, D.
    Deng, W.
    Rogers, E.
    Ung, J.
    Zhang, X.
    Zhang, H.
    Huang, Z.
    Whitten, J.
    Lim, J.
    Li, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1829 - S1829
  • [3] Safety and Preliminary Clinical Activity of Ropotrectinib ( TPX-0005), a ROS1/TRK/ALK Inhibitor, in Advanced ROS1 Fusion-Positive NSCLC
    Lin, J.
    Kim, D.
    Drilon, A.
    Doebele, R.
    Lee, J.
    Zhu, V.
    Ahn, M.
    Lim, J.
    Stopatschinskaja, S.
    Cui, J. J.
    Hyman, D.
    Camidge, R.
    Ou, S.
    Shaw, A.
    Cho, B. C.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S322 - S322
  • [4] TPX-0005, an ALK/ROS1/TRK inhibitor, overcomes multiple resistance mechanisms by targeting SRC/FAK signaling
    Zhai, Dayong
    Deng, Wei
    Huang, John
    Rogers, Evan
    Cui, J. Jean
    CANCER RESEARCH, 2017, 77
  • [5] Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibit ROS1/TRK/ALK Solvent-Front Mutations
    Drilon, Alexander
    Ou, Sai-Hong Ignatius
    Cho, Byoung Chul
    Kim, Dong-Wan
    Lees, Jeeyun
    Lin, Jessica J.
    Zhu, Viola W.
    Ahns, Myung-Ju
    Camidge, D. Ross
    Nguyen, Judy
    Zhai, Dayong
    Deng, Wei
    Huang, Zhongdong
    Rogers, Evan
    Liu, Juliet
    Whitten, Jeff
    Lim, John K.
    Stopatschinskaja, Shanna
    Hyman, David M.
    Doebele, Robert C.
    Cui, J. Jean
    Shaw, Alice T.
    CANCER DISCOVERY, 2018, 8 (10) : 1227 - 1236
  • [6] Potency of a new ALK/ROS1 inhibitor TPX-0005 to ALK G1202R mutation and ROS1 G2032R mutation
    Yoda, Satoshi
    Dardaei, Leila
    Prutisto-Chang, Kylie
    Cui, Jean
    Shaw, Alice T.
    Hata, Aaron N.
    CANCER RESEARCH, 2018, 78 (13)
  • [7] A phase 1 study of the next-generation ALK/ROS1/TRK inhibitor ropotrectinib (TPX-0005) in patients with advanced ALK/ROS1/NTRK plus cancers (TRIDENT-1).
    Drilon, Alexander E.
    Ou, Sai-Hong Ignatius
    Cho, Byoung Chul
    Kim, Dong-Wan
    Lee, Jeeyun
    Lin, Jessica Jiyeong
    Zhu, Viola Weijia
    Kim, HyeRyun
    Kim, Tae Min
    Ahn, Myung-Ju
    Camidge, D. Ross
    Lim, John K. C.
    Stopatschinskaja, Shanna
    Cui, Jingrong Jean
    Hyman, David Michael
    Doebele, Robert Charles
    Shaw, Alice Tsang
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [8] Preliminary Clinical Activity of Repotrectinib (TPX-0005) in Advanced ROS1 Fusion-Positive Non-Small Cell Lung Cancer
    Ou, S.
    Cho, B. C.
    Kim, D.
    Drilon, A.
    Lee, J.
    Lin, J.
    Zhu, V.
    Ahn, M.
    Camidge, D. R.
    Stopatschinskaja, S. Shanna
    Liu, J.
    Cui, J.
    Hyman, D.
    Doebele, R.
    Shaw, A.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (12) : S1047 - S1047
  • [9] TPX-0005, a novel ALK/ROS1/TRK inhibitor, effectively inhibited a broad spectrum of mutations including solvent front ALK G1202R, ROS1 G2032R and TRKA G595R mutants
    Cui, J. J.
    Zhai, D.
    Deng, W.
    Rogers, E.
    Huang, Z.
    Whitten, J.
    Li, Y.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S32 - S32
  • [10] LORLATINIB ALK/ROS1 inhibitor Treatment of non-small cell lung cancer
    Gajdosik, Z.
    DRUGS OF THE FUTURE, 2016, 41 (12) : 715 - 723
12